摘要
Call for standardization of fecal microbiota transplantation(FMT)The gut microbiota plays an important role in human health and disease.Dysbiosis is often recognized in patients with diseases of the digestive and other systems(Blaser,2019;Li et al.,2018b;Qin et al.,2018).FMT refers to the administration of fecal material containing distal gut microbiota from a healthy person(donor)to a patient(recipient)to restore the gut microecology of the recipient(Kelly et al.,2015).Clinical guidelines have strongly recommended FMT for the treatment of relapsed or refractory Clostridium difficile infection(CDI)(Mullish et al.,2018).FMT has also shown potential clinical benefits in many other diseases related to dysbiosis,including inflammatory bowel disease(IBD),irritable bowel syndrome(IBS),functional constipation(FC),liver diseases,metabolic syndrome,autism,and cancer(Huang et al.,2018;Li et al.,2018a;Zhang et al.,2018).Because of its broad curative potential,FMT has become a topic of great interest.More than 3,000 published articles have reported treatment of different diseases with FMT,and over 380 FMT trials have been registered on the ClinicalTrials.gov website.
基金
supported by the National Natural Science Foundation of China (81670493, 81730102)
Special Fund for the Construction of the Clinical Center of Tenth People’s Hospital of Tongji University (04.99.18001)
Emerging Cutting-Edge Technology Joint Research Projects of Shanghai (SHDC12017112)
Specialized Research Fund for the Combine Traditional Chinese and Western Medicine in General Hospital of Shanghai (ZHYY-ZXYJHZX-1-201704)
Research Fund of Shanghai Science and Technology Commission in the Field of Biomedicine (16431903600)
